

Supplementary Table 1 Interventional trials of drugs, biological products, or dietary supplements registered on ClinicalTrials.gov for the treatment of agitation in dementias

NCT Number	Study Title	Study status	Conditions	Interventions	First Posted
Trials in which agitation in dementia was a primary outcome					
NCT06781333	Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease.	Not yet recruitin g	Alzheimer Disease Agitation in Dementia	BIOLOGICAL: hMSC	4/6/2022
NCT06052254	Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type	Not yet recruitin g	Agitation	DRUG: 12 cm2 - 2 Active DMTS Patches DRUG: 6 cm2 - 1 Active and 1 Placebo DMTS 2 Patches DRUG: Placebo - 2 Placebo DMTS Patches	4/4/2022
NCT02168920	Aripiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type	Terminat ed	Agitation Associated With Dementia of the Alzheimer's Type	DRUG: 2 mg/day DRUG: 3 mg/day DRUG: 6 mg/day DRUG: Placebo (0 mg/day)	4/1/2022
NCT02719834	Behavioral Expressions in Alzheimer's Disease	Comple t ed	Alzheimer's Disease	DRUG: Acetaminophen OTHER:	3/31/2022

NCT04341467	Amisulpride Treatment for BPSD in AD Patients	Unknown	BPSD Amisulpride Olanzapine Dementia of the Alzheimer Type	Placebo DRUG: Amisulpride DRUG: Olanzapine	8/17/2020
NCT02446132	Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type	Terminated	Agitation in Patients With Dementia of the Alzheimer's Type	DRUG: AVP-786	8/3/2020
NCT04464564	Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type	Terminated	Agitation in Patients With Dementia of the Alzheimer's Type	DRUG: AVP-786 DRUG: Placebo	7/22/2020
NCT04408755	Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the	Terminated	Agitation in Patients With Dementia of the Alzheimer's Type	DRUG: AVP-786 DRUG: Placebo	7/22/2020

	Alzheimer's Type Efficacy, Safety and Tolerability of AVP-786				
NCT02442765	for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type Efficacy, Safety, and Tolerability of AVP-786	Completed	Agitation in Patients With Dementia of the Alzheimer's Type	DRUG: AVP-786 DRUG: Placebo	7/9/2020
NCT02442778	for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type Efficacy, Safety and Tolerability Study of AVP-923	Completed	Agitation in Participants With Dementia of the Alzheimer's Type	DRUG: AVP-786-18 DRUG: Placebo DRUG: AVP-786-28 DRUG: AVP-786-42.63	7/7/2020
NCT01584440	(Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease	Completed	Agitation Alzheimer's Disease	DRUG: AVP-923-20 DRUG: Placebo DRUG: AVP-923-30	6/17/2020
NCT04947553	A Study to Assess the Long-term Safety and Efficacy of AXS-05 in	Completed	Agitation in Patients With Dementia of the Alzheimer's Type Alzheimer Disease Agitation, Psychomotor	DRUG: AXS-05 (dextromethorphan-bupropion) DRUG:	6/9/2020

	Subjects With Alzheimer's Disease Agitation			Placebo			
NCT03226522	Addressing Dementia Via Agitation-Centered Evaluation	Completed	Agitation in Patients With Dementia of the Alzheimer's Type Alzheimer Disease Agitation,Psychomotor	DRUG: AXS-05 DRUG: 6/5/202 Bupropion DRUG: Placebo 0			
NCT05557409	A Study to Assess the Efficacy and Safety of AXS-05 in Subjects with Alzheimer's Disease Agitation	Completed	Agitation in Patients with Dementia of the Alzheimer's Type Alzheimer Disease Agitation	DRUG: AXS-05 DRUG: 5/29/20 Placebo 20			
NCT04797715	Assessing Clinical Outcomes in Alzheimer's Disease Agitation	Completed	Agitation in Patients With Dementia of the Alzheimer's Type Alzheimer Disease Agitation,Psychomotor	DRUG: AXS-05 DRUG: 5/4/202 Placebo 0			
NCT06808984	Study to Evaluate the Efficacy, Safety, and Tolerability of BMS- 986368, for the Treatment of Agitation in Participants With Alzheimer's Disease	Not yet recruiting	Agitation Alzheimer Disease	DRUG: BMS- 4/15/20 986368 DRUG: Placebo 20			
NCT03548194	A Study of BNC210 in Elderly Patients With	Completed	Agitation in the Elderly	DRUG: BNC210 DRUG: 4/10/20 Placebo 20			

	Agitation					
	Brexpiprazole for the					
	Long-term Treatment of					
NCT03724	Patients With Agitation	Comple	Agitation Associated With Dementia of the	DRUG: Brexpiprazole	3/31/20	
942	Associated With	ed	Alzheimer's Type		20	
	Dementia of the					
	Alzheimer's Type					
	Safety and Tolerability					
	Study of Flexible Dosing					
	of Brexpiprazole in the					
NCT01922	Treatment of Subjects	Comple	Agitation Associated With Alzheimer's	DRUG: Brexpiprazole,	3/25/20	
258	With Agitation	ed	Disease Alzheimer's Type Mental	OPC-34712	20	
	Associated With		Disorder Nervous System Diseases			
	Dementia of the					
	Alzheimer's Type					
	A Phase 3, 12-week,					
	Multicenter,					
	Randomized, Double-					
	blind, Placebo-					
NCT01862	controlled Trial to	Comple	Agitation Associated With Alzheimer's	DRUG: Brexpiprazole,	3/20/20	
640	Evaluate the Efficacy,	ed	Disease Alzheimer's Type Mental	OPC-34712 DRUG: Placebo	20	
	Safety, and Tolerability		Disorder Nervous System Diseases	Oral Tablet		
	of 2 Fixed Doses of					
	Brexpiprazole in the					

NCT03594123	Treatment of Alzheimer's Agitation A 12-week Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type Brexpiprazole for the Treatment of Patients With Agitation Associated With Dementia of the Alzheimer's Type	Completed	Alzheimer's Disease	DRUG: Brexpiprazole DRUG: Brexpiprazole	3/12/2020
NCT03620981	With Agitation Associated With Dementia of the Alzheimer's Type A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the	Completed	Agitation Associated With Dementia of the Alzheimer's Type	DRUG: Brexpiprazole DRUG: Placebo	3/3/2020
NCT03548584	Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the	Completed	Agitation Associated With Alzheimer's Dementia Alzheimer Dementia	DRUG: Brexpiprazole OTHER: Placebo	2/19/2020

NCT05276830	Alzheimer's Type An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With Dementia	Terminated	Agitation Dementia	DRUG: BXCL501 DRUG: BXCL501 DRUG: Placebo film	2/17/2020
NCT05665088	Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)	Terminated	Agitation Dementia	DRUG: BXCL501 DRUG: Matching Placebo	2/10/2020
NCT05271552	Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)	Completed	Agitation Dementia	DRUG: BXCL501 DRUG: Matching Placebo	2/5/2020
NCT03328676	The Effect of Cannabis on Dementia Related Agitation and Aggression	Completed	Agitation Related to Dementia	DRUG: Cannabis DRUG: Placebo oil	1/22/2020
NCT00898807	Citalopram for Agitation in Alzheimer's Disease	Completed	Alzheimer's Disease Agitation	DRUG: citalopram DRUG: placebo	1/18/2020
NCT01302340	Delta-THC in Behavioral Disturbances in	Completed	Dementia	DRUG: Delta-THC DRUG: placebo DRUG: Delta-THC	11/19/2019

	Dementia					
NCT05612711	Dronabinol for Agitation in Dementia Crossover Trial	Withdrawn	Dementia Severe Agitation, Psychomotor Behavioral Symptoms	Moderate Dementia	DRUG: Dronabinol	11/8/2019
NCT02792257	Trial of Dronabinol Adjunctive Treatment of Agitation in Alzheimer's Disease	Completed	Alzheimer's Disease		DRUG: Dronabinol (Marinol®) DRUG: Placebo	11/4/2019
NCT01735630	Efficacy and Safety Study of ELND005 as a Treatment for Agitation and Aggression in Alzheimer's Disease	Completed	Alzheimer's Disease		DRUG: ELND005 DRUG: Placebo	10/31/2019
NCT03108846	Escitalopram for Agitation in Alzheimer's Disease	Active not recruiting	Dementia		DRUG: Escitalopram DRUG: Placebo	10/9/2019
NCT01119638	Escitalopram Treatment for BPSD in Alzheimer's Disease in Comparison to Risperidone	Completed	Agitation Psychosis Alzheimer's Disease		DRUG: Escitalopram DRUG: Risperidone	10/3/2019
NCT03451760	Feru-guard for Behavioral Symptoms in Dementia	Unknown	Behavioral and Psychiatric Symptoms of Dementia		DRUG: Feru-guard 100M OTHER: Feru-guard 100M Placebo	9/24/2019

NCT01766336	A 36-Week Safety Extension Study of ELND005 as a Terminated Treatment for Agitation and Aggression in Alzheimer's Disease Cannabidiol Solution for the Treatment of Behavioral Symptoms in Older Adults With Mild Cognitive Impairment or Alzheimer's Dementia	Recruiting	Alzheimer's Disease	DRUG: Group 1 ELND005 DRUG: Group 2 ELND005	9/23/2019
NCT04075435	Clinical Trial on Agitation in Alzheimer's Dementia	Recruiting	Alzheimer Disease Anxiety Agitation, Psychomotor	DRUG: high CBD/low THC sublingual solution	9/19/2019
NCT05543681	ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease	Recruiting	Alzheimer Disease Agitation, Psychomotor Care Giving Burden NPS Aggression	DRUG: IGC-AD1-Active DRUG: IGC-AD1-Placebo	8/30/2019
NCT02817906	A Study to Assess the Efficacy and Safety of ITI-1284 in the	Terminated	Agitation in Dementia, Including Alzheimer's Disease	DRUG: ITI-007 DRUG: Placebo	8/12/2019
NCT06651567		Recruiting	Agitation Associated With Alzheimer's Dementia	DRUG: ITI-1284 DRUG: Placebo	8/5/2019

NCT06585787	Treatment of Agitation Associated With Alzheimer's Dementia A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)	Recruiting	Alzheimer Disease	DRUG: Placebo DRUG: KarXT	8/2/2019
NCT06126224	KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)	not recruiting	Psychosis Associated With Alzheimer's Disease	DRUG: Placebo DRUG: KarXT	7/30/2019
NCT04004702	Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE)	Not yet recruiting	Alzheimer Disease	DRUG: Levetiracetam	7/5/2019
NCT02862210	Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia	Completed	Frontotemporal Dementia (FTD)	DRUG: Lithium Carbonate DRUG: Placebo	7/2/2019

NCT02129348	Treatment of Psychosis and Agitation in Alzheimer's Disease	Completed	Alzheimer's Disease Psychosis Agitation	DRUG: Lithium DRUG: Placebo	6/28/2019
NCT00843518	Treatment for Aggression and Agitation in Patients With Alzheimer's Disease	Completed	Alzheimer's Disease	DRUG: LY451395 DRUG: Placebo	4/24/2019
NCT05397639	Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type	Recruiting	Agitation Alzheimer's Type Dementia	DRUG: Masupirdine 50 mg DRUG: Masupirdine 100 mg DRUG: Placebo	4/1/2019
NCT06217146	A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.	Terminated	Agitation, Psychomotor Disruptive Behavior Dementia Alzheimer Disease	DRUG: Medical Cannabis DRUG: Placebo Oil	3/13/2019
NCT00703430	Memantine on Aggression and Agitation of Alzheimer's Disease (AD)	Unknown	Alzheimer's Disease	DRUG: Memantine	3/7/2019
NCT03031184	Study of Mirtazapine for Agitation in Dementia	Completed	Dementia	DRUG: Mirtazapine OTHER: Placebo	2/28/2019

NCT05227118	MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)	Completed	Alzheimer's Disease	DRUG: MK-8189 DRUG: Placebo	1/30/2019
NCT03044249	A Study of MP-101 in Dementia-Related Psychosis and/or Agitation and Aggression	Terminated	Psychosis Dementia Aggression Agitation Alzheimer Dementia	DRUG: MP-101 DRUG: Placebo	1/24/2019
NCT05742698	Nabilone for Agitation in Frontotemporal Dementia	Recruiting	Frontotemporal Dementia Frontotemporal Dementia, Behavioral Variant Primary Progressive Aphasia bvFTD PPA FTD	DRUG: Nabilone DRUG: Placebo	12/12/2018
NCT04516057	Nabilone for Agitation Blinded Intervention Trial	Recruiting	Alzheimer Disease Agitation	DRUG: Nabilone OTHER: Placebo	12/5/2018
NCT06546995	Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With	Recruiting	Alzheimer's Disease Healthy Elderly	DRUG: NMRA-323511 DRUG: Placebo	11/9/2018

NCT06803823	Agitation Associated With Dementia Due to Alzheimer's Disease A Study of ONO-2020 in Patients With Agitation Associated With Alzheimer's Disease Dementia Efficacy of ORM-12741 on Agitation/Aggression Symptoms in Alzheimer's Disease	Recruiting	Agitation Associated With Alzheimer's Disease Dementia	DRUG: ONO-2020 DRUG: Placebo	11/7/2018
NCT02471196	Study Evaluating The Safety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil	Completed	Alzheimer's Disease	DRUG: ORM-12741 DRUG: ORM-12741 DRUG: Placebo	10/18/2018
NCT01712074	Study Evaluating The Safety And Efficacy Of PF-05212377 Or Placebo In Subjects With Alzheimer's Disease With Existing Neuropsychiatric Symptoms On Donepezil	Terminated	Alzheimer's Disease	DRUG: PF-05212377 (SAM-760) OTHER: Placebo	9/24/2018
NCT03118947	A Study of Pimavanserin for the	Completed	Agitation and Aggression in Alzheimer's Disease	DRUG: Pimavanserin	9/14/2018

NCT02992132	Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE) Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan	Terminated	Agitation and Aggression in Alzheimer's Disease	DRUG: Pimavanserin 34 mg DRUG: Pimavanserin 20 mg OTHER: Placebo	9/13/2018
NCT03393520	Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type	Completed	Agitation in Patients With Dementia of the Alzheimer's Type	DRUG: Placebo DRUG: AVP-786	8/31/2018
NCT01126099	Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease	Completed	Alzheimer's Disease	DRUG: Prazosin DRUG: Placebo	8/23/2018

NCT03710642	Prazosin for Agitation in Alzheimer's Disease Prospekta in the Treatment of Cognitive,	Completed	Alzheimer's Disease Disruptive Behavior	DRUG: Prazosin DRUG: Placebo oral capsule	8/8/2018
NCT04552041	Behavioral and Psychiatric Disorders in Patients With Vascular Dementia.	Completed	Vascular Dementia	DRUG: Prospekta DRUG: Placebo	7/24/2018
NCT00621647	Seroquel-Associated Dementia Agitation With	Completed	Alzheimer's Disease Vascular Dementia	DRUG: Quetiapine Fumarate DRUG: Quetiapine Fumarate DRUG: Placebo	7/20/2018
NCT05239390	SCI-110 for Alzheimer Disease and Agitation Efficacy of Chinese Traditional Medicine	Unknown	Alzheimer Disease	DRUG: SCI -110	7/5/2018
NCT05538507	"Smart Soup" in Cognition and Behavior Regulation in Alzheimer's Disease Sub-Lingual	Unknown	Alzheimer Disease Mild Cognitive Impairment	DRUG: smart soup DRUG: Donepezil DRUG: Memantine DRUG: Placebo	7/5/2018
NCT04251910	Dexmedetomidine in Agitation Associated With Dementia	Completed	Agitation,Psychomotor Dementia	DRUG: Sublingual film containing Dexmedetomidine DRUG: Sublingual Placebo Film	7/3/2018

NCT04436081	Effects of THC-Free CBD Oil on Agitation in Patients With Alzheimer's Disease	Unknown	Alzheimer Disease Dementia Major Neurocognitive Disorder With Aggressive Behavior	DRUG: THC-free CBD Oil DRUG: Placebo	6/13/2018
NCT00000179	Agitation in Alzheimer's Disease	Completed	Alzheimer Disease	DRUG: Trazodone DRUG: Haloperidol	6/7/2018
NCT02192554	Safety Follow-up Study for Subjects With Agitation Associated With Dementia of the Alzheimer's Type Who Previously Participated in a Double-blind Trial of Brexpiprazole or Placebo	Completed	Agitation Associated With Alzheimer's Disease Mental Disorder Nervous System Diseases	Alzheimer's Disease Alzheimer's	6/7/2018

Trials in which agitation in dementia was a secondary outcome

NCT01227564	Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease	Completed	Alzheimer's Disease	BIOLOGICAL: ACC-001 3 1/4g/ QS-21 50 1/4g BIOLOGICAL: ACC-001 10 1/4g/ QS-21 50 1/4g OTHER: Placebo-Phosphate buffered saline (PBS)	5/29/2018
NCT00818	A Phase 3 Study	Completed	Alzheimer's Disease	BIOLOGICAL: Immune	5/22/20

662	Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer's Disease	ed		Globulin Intravenous (Human), 10% 400 mg/kg BIOLOGICAL: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg BIOLOGICAL: Placebo solution: Human Albumin 0.25% - 4 mL/kg BIOLOGICAL: Placebo solution: Human Albumin 0.25% - 2 mL/kg BIOLOGICAL: Immune Globulin Intravenous (Human), 10% Solution BIOLOGICAL: Human albumin 0.25% DIETARY_SUPPLEMENT: Meal-Replacement Therapy BEHAVIORAL: Dietary Counseling DIETARY_SUPPLEMENT: MMFS-205-SR DIETARY_SUPPLEME	18
NCT01524887	Phase 3 IGIV, 10% in Alzheimer's Disease	Terminated	Alzheimer's Disease		5/11/2018
NCT03872375	Calorie Restriction and Brain Function in Mild Cognitive Impairment	Completed	Mild Cognitive Impairment		4/24/2018
NCT03531684	Efficacy and Safety of MMFS in Early AD	Completed	Alzheimer Disease		3/30/2018

				NT: Placebo
NCT01785628	The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	Completed	Parkinson's Disease With Dementia	DIETARY_SUPPLEMENT: Sarcosine 3/30/20 Capsule DIETARY_SUPPLEMENT: Placebo Capsule 18
NCT06797817	Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyric Acid Effects Via the Gut-Brain	Not yet recruiting	Alzheimer Disease (AD)	DIETARY_SUPPLEMENT: tributyrin OTHER: Placebo 3/15/20 18
NCT01369225	Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease	Completed	Alzheimer's Disease	DRUG: AAB-003 (PF-05236812) DRUG: AAB-003 (PF-05236812) DRUG: AAB-003 (PF-05236812) DRUG: AAB-003 (PF-05236812) 3/12/20 18
NCT01193608	Study Evaluating The Safety Of AAB-003 (PF-	Completed	Alzheimer's Disease	DRUG: AAB-003 (PF-05236812) DRUG: AAB-003 2/27/20 18

05236812) In Subjects
With Alzheimer's
Disease

(PF-05236812) | DRUG:
AAB-003 (PF-
05236812) | DRUG: AAB-003
(PF-05236812) | DRUG:
AAB-003 (PF-
05236812) | OTHER: Placebo

NCT05771
428 Study to Assess Adverse
Events, Change in
Disease Activity and
How Oral ABBV-552
Capsules Moves Comple
Through the Body of ed
Participants Aged 50 to
90 Years With Mild
Alzheimer's Disease
Alzheimer's Disease (AD)

DRUG: ABBV-552 | DRUG: 2/22/20
Placebo for ABBV-552 18

NCT05291
234 A Study to Assess Safety
of ABBV-916 and How
Intravenous ABBV-916
Moves Through Body Active
and Affects Brain not
Amyloid Plaque recruitin
Clearance in Adult g
Participants (Aged 50-90
Years) With Early
Alzheimer's Disease (AD)

DRUG: ABBV-916 | DRUG: 2/19/20
Placebo 18

	Alzheimer's Disease Safety and Tolerability Study Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease This is a Safety and Tolerability Study	Termina ted	Alzheimer's Disease	DRUG: ABT-126	2/5/201 8
NCT01690 195					
NCT01676 935	Evaluating a New Treatment for Subjects With Mild to Moderate Alzheimer's Disease A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Termina ted	Alzheimer's Disease	DRUG: ABT-126	1/31/20 18
NCT05310 071	Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type	Termina ted	Alzheimer's Disease	DRUG: Aducanumab DRUG: Placebo	1/26/20 18
NCT01438 060		Comple ted	Dementia, Alzheimer Type	DRUG: Aripiprazole (BMS- 337039) DRUG: Placebo	1/18/20 18
NCT04482	Study to Evaluate the	Unknow	Alzheimer Disease	DRUG: AstroStem DRUG:	1/8/201

413	Safety and Efficacy of n AstroStem in Treatment of Alzheimer's Disease An Open-Label Study to Assess the Long-term Safety of AXS-05 in Enrollin Subjects with Dementia g by of the Alzheimer's Type, invitatio ADVANCE-2 and n ACCORD-2 Extension Study		Agitation in Patients with Dementia of the Alzheimer's Type Alzheimer Disease Agitation, Psychomotor	Placebo	8
NCT06736 509				DRUG: AXS-05 (dextromethorphan- bupropion)	12/2/20 17
NCT02080 364	Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Termina Patients With Mild ted Alzheimer's Disease		Alzheimer's Disease	DRUG: Azeliragon DRUG: Placebo	11/29/2 017
NCT00996 918	A Long-Term Safety And Tolerability Study Termina Of Bapineuzumab In ted Alzheimer Disease Patients		Alzheimer Disease	DRUG: Bapineuzumab 0.5 mg/kg DRUG: Bapineuzumab 1.0 m/kg	11/7/20 17
NCT06514 066	Cannabidiol's Role in Not yet Dementia Management recruitin g		Dementia, Vascular Dementia, Mixed	DRUG: Cannabidiol Oil	11/1/20 17

	MEDical CANnabis for Improving Symptoms					
NCT05432206	During Severe DEMENTia Disorders in Long-term Care Facility in Geneva	Completed	Dementia with Behavioral Disturbance	DRUG: Cannabis Sativa Oil DRUG: Placebo	11/1/2017	
NCT06014424	Cannabidiol Medication Intervention Trial Discontinuation of	Recruiting	Alzheimer Disease	DRUG: CBD OTHER: Placebo	10/10/2017	
NCT02035982	Cholinesterase Inhibitors for the Treatment of Severe Alzheimer's Disease A Study of Crenezumab Versus Placebo to Evaluate the Efficacy	Completed	Alzheimer's Disease Dementia	DRUG: Cholinesterase Inhibitor DRUG: Placebo	9/14/2017	
NCT03114657	and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)	Terminated	Alzheimer's Disease	DRUG: Crenezumab DRUG: Placebo	9/1/2017	
NCT02670083	A Study Evaluating the Efficacy and Safety of Crenezumab Versus	Terminated	Alzheimer's Disease	DRUG: Crenezumab DRUG: Placebo	7/21/2017	

Placebo in Participants
With Prodromal to Mild
Alzheimer's Disease
(AD).

Daridorexant to Treat
Insomnia in Patients
With Mild Cognitive
Impairment and Mild to
Moderate Alzheimer
Disease

NCT05924
425

Recruiti
ng

Alzheimer
Disorder | Sleep

Disease | Insomnia

DRUG: Daridorexant 50
mg | DRUG:

Placebo | PROCEDURE:

Polysomnography | BEHAV
IORAL:

Neuropsychological
assessment | BEHAVIORAL

: Questionnaires on sleep
and behavioural

problems | PROCEDURE:

Actimetrics | PROCEDURE:

24-hour Ambulatory Blood
Pressure Monitoring

(ABPM | OTHER:

Biomarker assay

DRUG: delta-9-
tetrahydrocannabinol

(delta-THC) | DRUG:

Placebo | DRUG:

Acetaminophen | DRUG:

5/19/20
17

NCT01608
217

Delta-THC in Dementia

Comple
ted

Behavioural
Disturbances | Pain | Dementia | Alzheimer's
Dementia | Vascular Dementia

DRUG: delta-9-
tetrahydrocannabinol

(delta-THC) | DRUG:

Placebo | DRUG:

Acetaminophen | DRUG:

5/10/20
17

				Acetaminophen	
NCT00912288	A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease	Terminated	Alzheimer Disease	DRUG: Dimebon 20 mg po TID DRUG: Placebo po TID	4/18/2017
NCT01066546	An Extension To The B1451006 Protocol To Evaluate The Safety and Efficacy of Dimebon In Subjects With Moderate-to-Severe Alzheimer's Disease	Terminated	Alzheimer's Disease	DRUG: Dimebon tablet for oral administration	4/14/2017
NCT01278407	A Study of E2020 in Patients With Dementia With Lewy Bodies (DLB), Followed by a Long-term Extension Phase	Completed	Dementia With Lewy Bodies (DLB)	DRUG: Donepezil 5 mg DRUG: Donepezil 10 mg DRUG: Donepezil matched placebo	4/11/2017
NCT02097056	Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease	Completed	Alzheimer's Disease	DRUG: Donepezil HCL	2/6/2017

NCT00571064	The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility	Completed	Mild to Severe Alzheimer's Disease	DRUG: Donepezil HCl	1/25/2017
NCT00477659	Neural Correlates In Mild Alzheimer's Disease	Completed	Alzheimer's Disease	DRUG: Donepezil hydrochloride	1/9/2017
NCT01362686	Comparative Research of Alzheimer's Disease Drugs	Terminated	Dementia Alzheimer's Disease	DRUG: Donepezil DRUG: Galantamine DRUG: Rivastigmine	12/22/2016
NCT06745583	A Phase 2 Study to Assess the Safety of EI-1071 and the Effects of EI-1071 on Neuroinflammation in Alzheimer's Disease Patients	Recruiting	Mild, Moderate, or Severe Alzheimer's Disease	DRUG: EI-1071 tablet, oral	12/14/2016
NCT01009476	Long-term Use of Galantamine Versus Nootropics (Memory Enhancing Drugs) in	Completed	Dementia Alzheimer Disease Dementia, Vascular	DRUG: Galantamine DRUG: Nootropics (ginkgo biloba, nicergoline, piracetam, or	10/14/2016

	Patients With Alzheimer's Dementia Under Conditions of Daily Routine			others)		
NCT01224 106	A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease	Comple ted	Alzheimer's Disease	DRUG: Gantenerumab DRUG: Placebo	8/10/20 16	
NCT03520 998	A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease	Comple ted	Alzheimer Disease Mild to Moderate Alzheimer Disease	DRUG: GRF6019	7/21/20 16	
NCT03765 762	A Study to Assess the Safety of GRF6019 Infusions in Subjects With Severe Alzheimer's Disease	Comple ted	Severe Alzheimer Disease	DRUG: GRF6019 OTHER: Placebo	7/12/20 16	
NCT05303 701	GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's	Not yet recruitin g	Moderate to Severe Alzheimer's Disease	DRUG: GV1001 Placebo DRUG: 1.12mg	6/29/20 16	

	Disease(AD)					
NCT01736579	Long-Term Study of IGIV, 10% in Alzheimer's Disease	Terminated	Alzheimer's Disease	DRUG: Immune Globulin Intravenous (Human), 10% (IGIV, 10%)	6/15/2016	
	Study To Evaluate the Efficacy, Safety and Tolerability of E2027					
NCT03467152	(Hereinafter Referred to as Irseontrine) in Participants With Dementia With Lewy Bodies	Completed	Dementia With Lewy Bodies	DRUG: Irseontrine DRUG: Placebo	6/7/2016	
	Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia					
NCT02078310	A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease	Completed	Alzheimer's Disease	DRUG: ITI-007 DRUG: Placebo DRUG: ITI-007 DRUG: Placebo	4/6/2016	
NCT06544616	in Participants With Preclinical Alzheimer's Disease	Recruiting	Preclinical Alzheimer's Disease	DRUG: JNJ-64042056 DRUG: Placebo	3/3/2016	
NCT01354691	Safety and Efficacy Study of Ladostigil in Mild to Moderate	Completed	Alzheimer's Disease Dementia Memory Loss Cognitive Impairment	DRUG: ladostigil hemitartrate	2/19/2016	

	Probable Alzheimer's Disease				
NCT03001557	Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia	Completed	Irregular Sleep-Wake Rhythm Disorder	DRUG: Lemborexant 2.5 mg DRUG: Lemborexant 5 mg DRUG: Lemborexant 10 mg DRUG: Lemborexant 15 mg DRUG: Lemborexant-matched placebo	2/1/2016
NCT03305809	A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)	Completed	Lewy Body Dementia	DRUG: LY3154207 DRUG: Placebo	1/29/2016
NCT00000171	Study of Melatonin: Sleep Problems in Alzheimer's Disease	Completed	Alzheimer Disease Dyssomnias	DRUG: Melatonin	1/13/2016
NCT00649220	Memantine and Antipsychotics Use	Terminated	Alzheimer's Disease	DRUG: Memantine	10/26/2015
NCT00866	Donepezil and	Unknown	Moderate to Severe Alzheimer's Disease	DRUG: Memantine DRUG:	6/29/20

060	Memantine in Moderate to Severe Alzheimer's Disease	n		Donepezil DRUG: Placebo	15
	Efficacy and Safety of			donepezil DRUG: Placebo	
NCT00857649	Memantine in Moderate to Severe Alzheimer's Disease	Terminated	Alzheimer's Disease	memantine	
	Memantine (10mg BID)			DRUG: Memantine DRUG: Placebo	6/15/2015
NCT00545974	for the Frontal and Temporal Subtypes of Frontotemporal Dementia	Completed	Frontal Lobe Dementia Frontotemporal Lobe Dementia Semantic Dementia	DRUG: memantine DRUG: Placebo pill	5/18/2015
NCT01458470	A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease	Completed	Huntington Disease	DRUG: Memantine OTHER: Placebo	5/13/2015
NCT04044131	Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients	Completed	Alzheimer Disease Parkinson Disease	DRUG: Metabolic Cofactor Supplementation DRUG: Sorbitol	5/13/2015
NCT06538116	A Study of Mevidalen (LY3154207) in Participants With	Recruiting	Alzheimer Disease	DRUG: Mevidalen DRUG: Placebo	5/8/2015

	Alzheimer's Disease						
	A Study to Assess the Efficacy and Safety of						
NCT06887192	ML-007C-MA for the Treatment of Alzheimer's Disease	Not yet recruiting	Psychosis Associated with Alzheimer's Disease	DRUG: ML-007C-MA DRUG: Placebo	4/14/2015		
	Psychosis						
	Safety, and Efficacy of a						
NCT03402503	New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease	Completed	Alzheimer Disease	DRUG: Montelukast buccal film OTHER: Placebo buccal film	3/5/2015		
	Safety and Efficacy of						
NCT02351882	Nabilone in Alzheimer's Disease	Completed	Alzheimer Disease Agitation Weight Loss Pain Oxidative Stress	DRUG: Nabilone DRUG: Placebo	1/30/2015		
	Cognitive Effects of Oral						
NCT04001517	p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies	Completed	Dementia With Lewy Bodies (DLB)	DRUG: Neflamapimod	1/29/2015		
	RewinD-LB - Clinical	Active					
NCT05869669	Study of Neflamapimod in Patients with Dementia with Lewy	not recruiting	Dementia with Lewy Bodies	DRUG: Neflamapimod DRUG: Placebo	11/20/2014		

Bodies

NCT04052737	PMZ-1620 (Sovate tide) in Mild to Moderate Alzheimer's Disease	Completed	Alzheimer Disease Dementia	DRUG: Normal Saline along with standard treatment DRUG: PMZ-1620 (sovateltide) along with standard treatment	6/20/2014
NCT04793659	Fasudil fOr redUcing elopemeNt and Spatial Disorientation	Completed	Dementia	DRUG: Oral Fasudil 90 mg/day DRUG: Oral Fasudil 180 mg/day DRUG: Oral Placebo	5/28/2014
NCT01324518	Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease	Completed	Alzheimer's Disease	DRUG: ORM-12741 DRUG: ORM-12741 DRUG: Placebo for ORM-12741	5/2/2014
NCT03867253	Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease	Completed	Mild to Moderate Alzheimer's Disease	DRUG: ORY-2001 Low dose DRUG: ORY-2001 High dose DRUG: Placebo	4/29/2014
NCT01021696	Pain in Patients With Dementia and Behavioural	Completed	Dementia Pain Agitation	DRUG: Paracetamol DRUG: Morphine DRUG:	3/26/2014

Disturbances

Buprenorphine

plaster | DRUG: Pregabalin

A Study to Evaluate the
Safety, Tolerability, and

NCT01028 Blood Levels of PF- Termina
911 03654746 in Subjects ted
With Mild to Moderate
Alzheimer's Disease

Alzheimer's Disease

DRUG: PF- 3/6/201
03654746 | DRUG: Placebo 4

NCT00930 A Study Of PF-04447943
059 Compared To Placebo In
Subjects With Mild To
Moderate Alzheimer's
Disease

Alzheimer's Disease

DRUG: PF- 3/5/201
04447943 | DRUG: Placebo 4

Comparing

NCT05590 Antipsychotic Recruti
637 Medications in LBD ng
Over Time

Parkinson's Disease Psychosis | Dementia
With Lewy Bodies

DRUG: 1/14/20
Pimavanserin | DRUG: 14
Quetiapine

NCT00895 Study Comparing 3
895 Dosage Levels Of SAM-
531 In Outpatients With Termina
Mild To Moderate ted
Alzheimer Disease

Alzheimer Disease

DRUG: Placebo | DRUG:
SAM-531 1.5 mg | DRUG:
SAM-531 3.0 mg | DRUG: 12/24/2
SAM-531 5.0 mg | DRUG: 013
Donepezil

NCT01529 Efficacy, Safety and Complet
619 Tolerability of ed

Alzheimer's Disease

DRUG: Rivastigmine 11/29/2
transdermal patch 013

	Rivastigmine Patch in Patients With Mild to Moderate Alzheimer's Disease Switched From Cholinesterase Inhibitors						
NCT01025466	Exelon Patch and Combination With Memantine Comparative Trial	Completed	Alzheimer's Disease	DRUG: Rivastigmine transdermal patch (Exelon patch), memantine DRUG: Rivastigmine transdermal patch	10/9/2013		
NCT00550420	Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers	Terminated	Alzheimer's Disease	DRUG: Rosiglitazone XR	8/14/2013		
NCT00490568	Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers	Terminated	Alzheimer's Disease	DRUG: Rosiglitazone XR	8/12/2013		
NCT03462121	A Clinical Study Evaluating the Efficacy and Safety of RPh201	Completed	Mild to Moderate Dementia Due to Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease	DRUG: RPh201 OTHER: Placebo	7/4/2013		

	Treatment in Individuals With Alzheimer's Disease With or Without Coexisting Cerebrovascular Disease Study Evaluating Intepirdine (RVT-101) in				
NCT02585 934	Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study Phase II Trial to Evaluate Safety and Efficacy of GM- CSF/Sargramostim in Alzheimer's Disease	Comple ted	Alzheimer's Disease	DRUG: RVT-101 DRUG: Placebo	5/24/20 13
NCT04902 703	A Study of Seltorexant in Participants With Probable Alzheimer's Disease	Recruti ng	Alzheimer Disease	DRUG: Sargramostim DRUG: Saline - placebo comparator	5/16/20 13
NCT05307 692	A Research Study Investigating Semaglutide in People	Comple ted	Alzheimer Disease	DRUG: Seltorexant DRUG: Placebo	3/22/20 13
NCT04777 396	Early Alzheimer's Disease	Active not recruitin	Early Alzheimer's Disease	DRUG: Semaglutide DRUG: Placebo (semaglutide)	2/7/201 3

NCT04777409	With Early Alzheimer's Disease (EVOKE) A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) Safety, Efficacy and Dose Titration of	g Active not recruiting	Early Alzheimer's Disease	DRUG: Semaglutide DRUG: Placebo (semaglutide)	1/11/2013
NCT01453569	Sodium Oligomannurrate Capsule on Mild to Moderate Alzheimer's Disease	Completed	Alzheimer Disease Cognitive Impairment	DRUG: Sodium oligomannurrate 600mg DRUG: Sodium oligo-mannurrate 900mg DRUG: Placebo	12/6/2012
NCT05644262	Life's End Benefits of CannaBidiol and Tetrahydrocannabinol A Long Term Extension Study to Assess the	Recruiting	Agitation Dementia	DRUG: T2:C100 DRUG: Placebo	12/3/2012
NCT05476783	Safety of TB006 in Participants With Alzheimer's Disease	Terminated	Alzheimer's Disease	DRUG: TB006	11/29/2012
NCT05074498	Study to Assess the Safety, Tolerability, Pharmacokinetics,	Completed	Alzheimer's Disease	DRUG: TB006 DRUG: Placebo	11/28/2012

	Pharmacodynamics, and Efficacy of TB006 in Participants With Alzheimer's Disease				
NCT00604 591	Effects of Tolcapone on Frontotemporal Dementia	Comple ted	Frontotemporal Lobar Degeneration	DRUG: Tolcapone DRUG: Placebo	10/29/2 012
NCT00744 978	Evaluation of the Efficacy of Varenicline on Cognition, Safety, Tolerability and Pharmacokinetics in Subjects With Mild-to- Moderate Alzheimer's Disease	Comple ted	Alzheimer's Disease	DRUG: Varenicline DRUG: Placebo	10/26/2 012
NCT01739 348	An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)	Termina ted	Alzheimer's Disease	DRUG: Verubecestat (Part I and Part II) DRUG: Verubecestat (Part I and Part II) DRUG: 2/2/201 Verubecestat (Part I and 2 Part II) DRUG: Placebo (Part I) DRUG: Verubecestat (Part II)	
NCT06570	Use of a Cannabinoids	Recruiti	Alzheimer Disease	OTHER:	2/26/20

928	as a Treatment Strategy for Alzheimer's Disease	ng					Cannabis OTHER: Placebo	07
							OTHER: Placebo DIETARY_SUPPL EMENT: Nicotinamide Riboside supplementation 1000mg daily in total DIETARY_SUPPLEM ENT: Nicotinamide Riboside dose escalation (up to 3000 mg daily in total)	10/31/2 003
NCT05617 508	Optimization Trial of Nicotinamide Riboside in Alzheimer's Disease	not recruiting	Active	Alzheimer Disease Dementia				
NCT06704 971	Assessing Cognitive Decline at Home An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US	Recruiti ng	Termina ted	Mild Cognitive Alzheimers Dementia Memory Impairment NPS	Mild Dementia Dementia			7/5/200 1
NCT05097 131				Alzheimers Disease				12/23/2 016